Concepedia

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

Joseph Proietto, A Rissanen, Joyce B. Harp, Ngozi Erondu, Qinfen Yu, S Suryawanshi, Michael E. Jones, Amy O. Johnson‐Levonas, Steven B. Heymsfield, Keith D. Kaufman,

International Journal of Obesity · 2010 · 67 citations · 15 references

DOI

Concepts

References

15

The PHQ-9

Kurt Kroenke, Robert L. Spitzer, Janet B. W. Williams · Journal of General Internal Medicine · 2001 · 44.2K citations · Full text

Obesity : Preventing and managing the global epidemic

D. S. Akram, Arne Astrup, Tola Atinmo et al. · Research at the University of Copenhagen (University of Copenhagen) · 2000 · 13K citations

, , +12

Validation and Utility of a Self-report Version of PRIME-MD<SUBTITLE>The PHQ Primary Care Study</SUBTITLE>

Robert L. Spitzer · JAMA · 1999 · 9.8K citations

, , +17

Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans

Arie Katz, Sridhar Nambi, Kieren J. Mather et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 3.8K citations · Full text

, , +9

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Luc F. Van Gaal, Aila Rissanen, André Scheen et al. · The Lancet · 2005 · 1.5K citations · Full text

, , +16